In the pivotal phase I TRANSCEND NHL 001 study, the CD19-directed CAR T-cell therapy lisocabtagene maraleucel demonstrated robust activity and manageable safety in relapsed/refractory LBCL.
Acalabrutinib with or without obinutuzumab significantly improved PFS compared with obinutuzumab plus chlorambucil.
Combination therapy with acalabrutinib, venetoclax, and obinutuzumab is highly active and safe as frontline therapy in CLL.
Venetoclax plus ibrutinib combination regimen in high-risk untreated patients with CLL showed increasing MRD negativity with continued treatment up to 2 years.
Initial results from the phase II CAPTIVATE trial demonstrated that ibrutinib plus venetoclax yielded high rates of undetectable MRD in patients with previously untreated CLL/SLL.
LOXO-305, a non-covalent BTK inhibitor, demonstrated preliminary antitumor activity and manageable safety in pretreated B-cell malignancies including those resistant to previous BTKi therapy.
Lisocabtagene maraleucel showed manageable toxicity and clinical activity in heavily pretreated patients with high-risk CLL/SLL who failed prior ibrutinib.
CRs observed with single-agent mosunetuzumab, a bispecific antibody, in patients with R/R B-cell NHL, including patients with aggressive disease.
Patients with relapsed/refractory B-cell NHL who showed clinical response to liso-cel reported greater quality-of-life improvement vs nonresponders.
KTE-X19, a CD19-directed CAR T-cell therapy, produced high and durable response rates in relapsed/refractory mantle cell lymphoma.
Despite axi-cel being used in older patients and in more patients with high-risk disease, real-world efficacy and safety data for axi-cel in patients with large B-cell lymphoma was comparable to findings from the registrational ZUMA-1 trial.